Clinical trial
Taxotere Prostate Cancer New Indication Registration Trial in China
NCT00436839 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00436839 |
|---|---|
| Title | Taxotere Prostate Cancer New Indication Registration Trial in China |
| Official title | An Multicenter, Randomized Study of Comparison of Docetaxel Plus Prednisone With Mitoxantrone Plus Prednisone in the Patients With Hormone-refractory (Androgen-independent) Metastatic Prostate Cancer |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Mitoxantrone, Prednisone |
| Enrollment | 228 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Feb 19, 2007 |
| Last update posted | Jul 9, 2012 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: